Triple-Negative Breast Cancer : An Update on Neoadjuvant Clinical Trials

Abstract EN

Triple-negative breast cancer (TNBC) is an aggressive malignancy with a poor prognosis despite the high rates of response to chemotherapy.

This scenario highlights the need to develop novel therapies and/or treatment strategies to reduce the mortality associated with TNBC.

The neoadjuvant setting provides a model for rapid assessment of treatment efficacy with smaller patient accruals and over shorter periods of time compared to the traditional adjuvant setting.

In addition, a clear surrogate endpoint of improved survival, known as pathologic complete response, already exists in this setting.

Here, we review current data from completed and ongoing neoadjuvant clinical trials for TNBC.